Halozyme Therapeutics (HALO) stock

Drug delivery , market cap $14B

Licensed drug delivery technology

Worth $14B

$102.98

+0.06%

As of Tuesday's close · Live for Pro members at the open

Why HALO fell 22% since Oct 29

Down 22% from Oct 29 to Nov 10.

Halozyme Therapeutics fell 22% from Oct 29 to Nov 10. 15 points of it came on Nov 6, the session after its Nov 5 results.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 5, 2026

Tell me next time HALO moves

Free account, no card. An optional alert when HALO moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →1 more reason why HALO fell 22% since Oct 29, from its filings, with the timeline and its peers, for Pro members.

Why HALO still beats the market over three years

Up 181% over the three years to Nov 9 while the S&P 500 rose 80%; down 21% since Oct 29.

8 reasons, from its filings, with the timeline, for Pro members.

Quality Score

Above Average

In its industry

#32of 281

Biotech

Checks firing

1of 14

Trending up

From 52-week high

-23.1%

under its best in a year

Up:Above Average or better for 100 days in a row, the longest run since Dec 2024. Scores before Sep 10, 2026 were rebuilt.

HALO's Quality Score fell 1 point on Tue, Nov 10, to 13. Its 6-month gain fell to 45%, under 52.5%, and its 12-month gain is under 88%.

Follow HALO's trial news. Pro members can get an alert when Halozyme Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when HALO files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on HALO

Key facts on HALO
The company	Sales up 45% on the year
Its score	Up:Above Average or better for 100 days in a row The longest run since Dec 2024. Scores before Sep 10, 2026 were rebuilt.
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind HALO's 13, free with an account →5 more reasons behind HALO's 13, for Pro members.

HALO in the news

Mon Nov 9Halozyme director Matthew Posard sells $2.05M in HALO shares By Investing.com in.investing.com and 1 more · yesterday 8:09 AM ET HALO closed −0.7% that day.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

HALO catalysts

Coming up

After its last 4 reports it closed +0.6% on average, higher 2 of 4 times.

34 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for HALO

Its trials

A trial underway: 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismPhase 3 · Recruiting · 100 people · main data estimated Mar 2028 · NCT06689085

For Pro members: 39 filings.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

CEO Helen Torley sold 60,000 shares on Oct 8, under a planned sale. 18 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Helen Torley buys or sells

For Pro members: every trade, and Helen Torley’s 36 filings and quotes.

Get an alert when HALO files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How HALO ranks in Biotech

HALO is #32 of 281 by Quality Score.

How HALO ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	GLUEMonte Rosa Therapeutics		Open for its score
	GPCRStructure Therapeutics		Open for its score
	HELPHelus Pharma		Open for its score
	HOWLWerewolf Therapeutics		Open for its score
32	HALOHalozyme Therapeutics	1/14	13

Free cash flow over four quarters: HALO $886M, DNLI -$450M, IBRX -$297M, SRRK -$297M.

When does HALO report earnings, and what happens after?

Expected to report Tue Feb 16, after the close (in 98 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What HALO reported on Nov 5, 2026

The quarter

Sales of $493.0M, 39% more than a year ago; a profit of $2.01 a share, from $1.43.

“The 39% year-over-year increase was primarily driven by royalty revenue growth and an increase in product sales.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Royaltyup 44%	$341M69%	$308M64%	$236M67%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

8 more lines, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
FY2026
Total revenue	$1.860B to $1.925Braised

Figures as filed (SEC filing, Nov 5)

3 more outlook lines, for Pro members.

The numbers

Market value: $14B; today
Sales: $1.8B; up 45% on the year
Free cash flow: $886M; last 12 months

Sales grew 39% a year over 5 years, fiscal 2020 to 2025.

Its share count fell 2.6% a year over 5 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on HALO: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+6.8%+20.2%-15.7%

May 11Aug 6Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026After close	After close	-4.8%	-15.7%	not yet
Aug 6, 2026After close	After close	+4.9%	+20.2%	+17.4%
May 11, 2026After close	After close	+5.6%	+6.8%	+1.6%

HALO closed higher after 2 of its last 4 reports.

All 4 reports, and HALO's Quality Score going into each

HALO sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $1.4B. It made a profit in six of the eight years.

HALO has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on HALO, and all 14 on every stock.Get in free →

HALO RSI today: 28.8, below its 50-day, above its 200-day

Not scored

RSI 28.8, MACD below signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on HALO

What it does and how it makes money6 findingsRoyalties made up 62% of its revenue in fiscal 2025 ($868M of $1.40B), against 56% in fiscal 2024; product sales 27% and collaborative agreements 11%.SEC filing · Feb 17, 2026"We have multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027, an issued European patent which expires in 2029, and additional patents that are valid into 2029 …" (10-K for fiscal 2025)SEC filing · Feb 17, 2026
Where it stands3 findingsFor Pro members3 findings on where HALO stands: its cash, debt, and share count, for Pro members
What changed in its filings7 findings"In October 2026, we announced the specialized Dutch patent court of the Hague found Merck Sharp & Dohme B.V. ('MSD BV') …" (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026Completed its acquisition of Surf Bio, Inc. on Dec 22, 2025, for $305.0 million in total purchase consideration.SEC filing · Feb 17, 2026A new heading in its "Risk Factors" this year: "Workforce reduction at federal agencies and changes in U.S. trade policy, including tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners’ costs …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 17, 2026, against the one of Feb 18, 2025One partner made up 41% of its revenue in fiscal 2025, the same as in fiscal 2024; another made up 16%, up from 9% in fiscal 2024.SEC filing · Feb 17, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades HALO, for Pro members
Against its closest peers4 peersFree cash flow over four quarters: HALO $886M, DNLI -$450M, IBRX -$297M, SRRK -$297M.

13 more findings on HALO, each with its source, for Pro members.

HALO insider trades

HALO trades by Congress and the executive branch

One trade disclosed in the last six months. The newest:

SellGilbert Cisneros$1K to $15KHousetraded Sep 29, disclosed Oct 12(13 days later)

SellGilbert CisnerosHouse$1K to $15Ktraded Sep 29, disclosed Oct 12(13 days later)

See what Congress is buying across the market

HALO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Helen TorleyPresident and CEO · 29 trades
Nicole LaBrosseSVP, Chief Financial Officer · no trades on file
Cortney CaudillSVP, Chief Operating Officer · 3 trades
David A. RamsayEVP, President, Drug Delivery · no trades on file
Mark Howard SnyderSVP, Chief Legal Officer · no trades on file
Bernadette ConnaughtonDirector · 7 trades
Matthew L. PosardDirector · 2 trades
Mahesh KrishnanDirector · 1 trade

5 more officers and directors file at HALO.

See insider trades by person

Which ETFs hold HALO?

In ETFs: HALO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

423 employeesSan Diego, CAhalozyme.com

What Halozyme Therapeutics says it competes with

“The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary therapeutics.”

From its annual report, SEC filing · Feb 17, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on HALO and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move HALO's score: 5 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 12Gilbert Cisneros sold HALO$1K to $15K, disclosed Oct 12

Alerts are optional.

See HALO's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: HALO's Quality Score is 13 (Above Average), #32 of 281 in Biotech.

What does HALO's Quality Score say?

HALO scores 13 today, which Breakaway calls Above Average. It is #32 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 22% from Oct 29 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is HALO's Quality Score?

HALO scores 13 today, which Breakaway calls Above Average (11 to 14). That is #32 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind HALO's 13.

When does HALO report earnings?

Expected to report Tue Feb 16, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. HALO closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.